Arrowhead Pharmaceuticals Inc.

NASDAQ:ARWR   3:59:51 PM EDT
68.04
-1.25 (-1.80%)
Products, Regulatory

Arrowhead Announces Positive Interim Results From Phase 1B Study Of Aro-Hif2 For Treatment Of Clear Cell Renal Cell Carcinoma

Published: 07/06/2021 12:20 GMT
Arrowhead Pharmaceuticals Inc. (ARWR) - Arrowhead Announces Positive Interim Results From Phase 1b Study of Aro-hif2 for Treatment of Clear Cell Renal Cell Carcinoma.
Arrowhead Pharmaceuticals Inc - 17 Patients Have Been Enrolled to Receive Intravenous Injections of 225 Mg Or 525 Mg Weekly.
Arrowhead Pharmaceuticals - in Cohort 2, One Subject Had a Partial Response With About 65% Tumor Shrinkage and 5 Had a Best Response of Stable Disease.
Arrowhead Pharmaceuticals Inc - to Date, Investigational Aro-hif2 Has Been Generally Well Tolerated at Doses of Up to 525 Mg Weekly.